Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.

This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.

Listen to this podcast for a concise summary of the latest clinical practice guidelines for identifying glycemic targets and managing T2DM in various patient populations including, older adults, individuals with increased cardiac or renal risk, and those at risk for hypoglycemic events.

Step into the clinic and onto the game show floor! In this interactive game of Jeopardy! test your knowledge of GLP-1 RAs in various patient encounters where you can implement your knowledge of type 2 diabetes management algorithms and use shared decision with patients. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 09/30/2020 and they are subject to change as new information is published.

In this clinical coffee break, cardiologist Ty Gluckman and endocrinologist Archana Sadhu will explain why glucagon like peptide-1 receptor agonists (GLP-1 RA) are becoming increasingly prominent in diabetes algorithms and cardiovascular risk reduction. Faculty will review the clinical trial data on this class of medications as well as the mechanisms by which GLP-1 RA provide cardiovascular benefit. You will have the opportunity to engage with this activity, viewing resources and testing your knowledge with interactive questions and cases.

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

Practice-changing updates to the medical literature that are hot off the presses! Join Dr. Pam Kushner to discuss important changes in the 2021 ADA guidelines and examine recently published research on atrial fibrillation, lipids, reducing cardiovascular risk, coconut oil, patient communication, and much more!

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.

With the growing role of GLP-1 RAs in the management of diabetes, primary care providers are likely to find themselves discussing this class of medications with their patients. In this podcast, Dr. Michelle Magee will focus on barriers that patients may face to starting a GLP-1 RA and common questions that emerge in patient teaching. Faculty will review ways to troubleshoot these challenges and empower the clinician to engage in effective dialogue around this drug class. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 11/18/2020 and they are subject to change as new information is published.